Literature DB >> 32562813

Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer.

Han Shuwen1, Yang Xi2, Pan Yuefen3, Xu Jiamin4, Qi Quan5, Liao Haihong6, Jiang Yizhen7, Wu Wei8.   

Abstract

BACKGROUND: The gut microbiome changes are related to the colorectal cancer (CRC). Chemotherapy is one of the main treatment methods for CRC.
PURPOSE: To explore the effect of chemotherapy on the gut bacteria and fungi in CRC.
METHODS: Total of 11 advanced CRC patients treated with the FOLFIRI regimen, 15 postoperative CRC patients treated with the XELOX regimen, and corresponding CRC patients without surgery and chemotherapy were recruited. The 16S ribosomal RNA and ITS sequences were sequenced, and bioinformatics analysis was executed to screen for the distinctive gut microbiome.
RESULTS: The abundances of Veillonella, Humicola, Tremellomycetes and Malassezia were increased in postoperative CRC patients treated with the XELOX regimen. The abundances of Faecalibacterium, Clostridiales, phascolarctobacterium, Humicola and Rhodotorula were decreased, and the abundances of Candida, Magnusiomyces, Tremellomycetes, Dipodascaceae, Saccharomycetales, Malassezia and Lentinula were increased in advanced CRC patients treated with the FOLFIRI regimen. The abundances of Humicola, Rhodotorula, and Magnusiomyces were decreased, and the abundances of Candida, Tremellomycetes, Dipodascaceae, Saccharomycetales, Malassezia and Lentinula were increased in advanced CRC patients treated with the FOLFIRI regimen combined with cetuximab compared with those treated with the FOLFIRI regimen alone.
CONCLUSIONS: The community structure of gut bacteria and fungi changes in chemotherapy on CRCs.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Capecitabine; Cetuximab; Chemotherapy; Colorectal cancer; Irinotecan; Microbiome

Mesh:

Substances:

Year:  2020        PMID: 32562813     DOI: 10.1016/j.micpath.2020.104343

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  3 in total

1.  HMGB3 is a Potential Therapeutic Target by Affecting the Migration and Proliferation of Colorectal Cancer.

Authors:  Wenjing Gong; Yang Guo; Hang Yuan; Xinye Hu; Rui Chai; Boan Zheng; Ziang Wan; Shiliang Tu
Journal:  Front Cell Dev Biol       Date:  2022-05-31

2.  Pre-Administration of Berberine Exerts Chemopreventive Effects in AOM/DSS-Induced Colitis-Associated Carcinogenesis Mice via Modulating Inflammation and Intestinal Microbiota.

Authors:  Jiaqiang Deng; Lili Zhao; Xieyong Yuan; Yan Li; Junyang Shi; Hua Zhang; Yuxuan Zhao; Liping Han; Huani Wang; Yan Yan; Hong Zhao; Haojie Wang; Fangdong Zou
Journal:  Nutrients       Date:  2022-02-09       Impact factor: 5.717

3.  Changes of gut microbiota in colorectal cancer patients with Pentatrichomonas hominis infection.

Authors:  Hongbo Zhang; Yanhui Yu; Jianhua Li; Pengtao Gong; Xiaocen Wang; Xin Li; Yidan Cheng; Xiuyan Yu; Nan Zhang; Xichen Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-08-31       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.